![Yale @ AWV-7785[57].jpg](https://images.squarespace-cdn.com/content/v1/66f1a668cb2280496659b3a0/f6e751ae-7da8-4189-8a99-08fc362f006f/Yale+%40+AWV-7785%5B57%5D.jpg)
Consortium Member of the Month
Our consortium member of the month for the month of November goes to Claire Borron from Core A at Mount Sinai Health System!
Claire Borron
Claire Borron joined our team at Mount Sinai last year and has seamlessly adapted to the complexities of the MPN-RC with exceptional professionalism and grace. As a Research Program Director and member of Core A, Claire skillfully manages the consortium’s financial and administrative operations with precision and care. Throughout our time working with her, Claire has consistently demonstrated the core qualities of effective leadership: optimism, clear and thoughtful communication, and an unwavering commitment to advancing the collective goals of the consortium. Claire, we are deeply grateful for your contributions and leadership. Your presence has infused the consortium with renewed positivity, collaboration, and a shared drive toward excellence.
Nominated by: Dr. Ronald Hoffman
Claire, thank you so much for all of the phenomenal work you have done for the consortium.
Keep up the great work!
Title: Long-read sequencing unmasks a cryptic three-way translocation resulting in an ETV6::PDGFRB fusion
Author(s): Joseph Tripodi, Douglas Tremblay, Daiva Ahire, and Vesna Najfeld
MPN-RC Monthly Publication
MPN-RC Updates: ASH Conference 2024
-
![]()
ASH Conference 2024
(Left to Right: Susan Geyer, Carolyn Mead-Harvey, and Dr. Amylou Dueck) The Mayo Clinic group from the MPN Research Consortium attended the American Society of Hematology 2024 Conference in San Diego, California from December 7th - 10th.
-
![]()
ASH Conference 2024
Dr. Shivani Handa presents her ASH abstract “243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms”. View the abstract here!
-
![]()
ASH Conference 2024
Dr. Anna Rita Migliaccio asking after the talk at the plenary session on megakaryocytes in the elderly whether the GATA1low megakaryocytes which are enriched in the elderly represent an enrichment in the immune-megakaryocte subpopulations.
-
Bridget Kelly Marcellino, MD,PhD
873 Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
-
Shivani Handa, MD
243 TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
